A Single Center, Randomized, Open-Label, Dose Escalating Phase I Study to Evaluate the Safety of Intramuscularly Administered DNA Vaccine (HB-110) Combined With Oral Antiviral (Adefovir) in Subjects With Chronic Hepatitis B Over a 48-Week Period

Trial Profile

A Single Center, Randomized, Open-Label, Dose Escalating Phase I Study to Evaluate the Safety of Intramuscularly Administered DNA Vaccine (HB-110) Combined With Oral Antiviral (Adefovir) in Subjects With Chronic Hepatitis B Over a 48-Week Period

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2013

At a glance

  • Drugs Adefovir; GX 110
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Aug 2012 Actual end date (1 Dec 2010) added as reported by ClinicalTrials.gov.
    • 01 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Aug 2008 Official Title amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top